ARTICLES|ONLINE FIRST Cyclophosphamide added to glucocorticoids in acute exacerbation of idiopathic pulmonary fibrosis (EXAFIP): a randomised, double-blind, placebo-controlled, phase 3 trial Jean-Marc Naccache, Stéphane Jouneau, Morgane Didier, et al Lancet Respir Med Published:September 07, 2021 DOI:https://doi.org/10.1016/S2213-2600(21)00354-4 Summary Background The use of cyclophosphamide in patients with acute exacerbation of idiopathic pulmonary ...

ARTICLES|ONLINE FIRST Awake prone positioning for COVID-19 acute hypoxaemic respiratory failure: a randomised, controlled, multinational, open-label meta-trial Stephan Ehrmann, Jie Li, Miguel Ibarra-Estrada, et al Lancet Respir Med Published:August 20, 2021 DOI:https://doi.org/10.1016/S2213-2600(21)00356-8 Summary Background Awake prone positioning has been reported to improve oxygenation for patients with COVID-19 in retrospective and observational s...

ARTICLES | ONLINE FIRST Inhaled isoflurane via the anaesthetic conserving device versus propofol for sedation of invasively ventilated patients in intensive care units in Germany and Slovenia: an open-label, phase 3, randomised controlled, non-inferiority trial Andreas Meiser, Thomas Volk, Jan Wallenborn, et al Lancet Respir Med Published:August 26, 2021 DOI:https://doi.org/10.1016/S2213-2600(21)00323-4 Summary Background Previous studies indicate tha...

ARTICLES|ONLINE FIRST Daily testing for contacts of individuals with SARS-CoV-2 infection and attendance and SARS-CoV-2 transmission in English secondary schools and colleges: an open-label, cluster-randomised trial Bernadette C Young, David W Eyre, Saroj Kendrick, et al Lancet Published:September 14, 2021 DOI:https://doi.org/10.1016/S0140-6736(21)01908-5 Summary Background School-based COVID-19 contacts in England have been asked to self-isolate at home...

Original Investigation September 21, 2021 Effect of Probiotics on Incident Ventilator-Associated Pneumonia in Critically Ill Patients: A Randomized Clinical Trial Jennie Johnstone, Maureen Meade, François Lauzier, et al JAMA. 2021;326(11):1024-1033. doi:10.1001/jama.2021.13355 Abstract Importance  Growing interest in microbial dysbiosis during critical illness has raised questions about the therapeutic potential of microbiome modifi...

ONLINE FIRST (FREE ACCESS) OriginalsManagement of arterial partial pressure of carbon dioxide in the first week after traumatic brain injury: results from the CENTER-TBI studyCiterio G. et al.Occurrence and timing of withdrawal of life-sustaining measures in traumatic brain injury patients: a CENTER-TBI studyvan Veen E. et al. Correspondances“L’histoire se répète”, one size does not fit allKuindersma M. and Spronk P.E.“L'histoire se répète”, one size does not fi...

ORIGINAL ARTICLE Protection of BNT162b2 Vaccine Booster against Covid-19 in Israel Yinon M. Bar-On, Yair Goldberg, Micha Mandel, et al N Engl J Med September 15, 2021DOI: 10.1056/NEJMoa2114255 Abstract BACKGROUND On July 30, 2021, the administration of a third (booster) dose of the BNT162b2 messenger RNA vaccine (Pfizer–BioNTech) was approved in Israel for persons who were 60 years of age or older and who had received a second dose of vaccine at lea...

ARTICLES| VOLUME 398, ISSUE 10302, P747-758, AUGUST 28, 2021 1-year outcomes in hospital survivors with COVID-19: a longitudinal cohort study Lixue Huang, Qun Yao, Xiaoying Gu, et al Lancet 2021; 398: 747-758 Summary Background The full range of long-term health consequences of COVID-19 in patients who are discharged from hospital is largely unclear. The aim of our study was to comprehensively compare consequences between 6 months and 12 m...

ARTICLES|ONLINE FIRST Haemodynamic-guided management of heart failure (GUIDE-HF): a randomised controlled trial JoAnn Lindenfeld, Michael R Zile, Akshay S Desai, et al Lancet Published:August 27, 2021 DOI:https://doi.org/10.1016/S0140-6736(21)01754-2 Summary Background Previous studies have suggested that haemodynamic-guided management using an implantable pulmonary artery pressure monitor reduces heart failure hospitalisations in patients with moderatel...

ORIGINAL ARTICLE Early Convalescent Plasma for High-Risk Outpatients with Covid-19 Frederick K. Korley, Valerie Durkalski-Mauldin, Sharon D. Yeatts, et al N Engl J Med August 18, 2021DOI: 10.1056/NEJMoa2103784 Abstract BACKGROUND Early administration of convalescent plasma obtained from blood donors who have recovered from coronavirus disease 2019 (Covid-19) may prevent disease progression in acutely ill, high-risk patients with Covid-19. METHODS I...